Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

OBJECTIVE: To demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira. METHODS: Patients with active rheumatoid arthritis on stable methotrexate were randomised to BI 695501 or Humira in a double-blind, parallel-group, equivalence study. At week 24, patients were re...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B, Alonso-Ruiz, Alberto, Klimiuk, Piotr A, Lee, Eric C, Peter, Nuala, Sonderegger, Ivo, Assudani, Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965346/
https://www.ncbi.nlm.nih.gov/pubmed/29514803
http://dx.doi.org/10.1136/annrheumdis-2017-212245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965346/
https://www.ncbi.nlm.nih.gov/pubmed/29514803
http://dx.doi.org/10.1136/annrheumdis-2017-212245

Ejemplares similares